The presence of MGMT (O6-methylguanine methyltransferase) promoter methylation and tumor mutational burden (TMB) were associated with mismatch repair (MMR) gene alterations, suggesting that evaluation of MMR genes for both biological and therapeutic considerations may be reasonable in GBM [15]. The gene discussed is MRC1; the disease is glioblastoma.